Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation Wildcard
…
3,229€
-0,89%
Echtzeit-Aktienkurs Arbutus Biopharma Corp.
Bid:
Ask:
Nachrichten zur Arbutus Biopharma Corp. Aktie
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
…
Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse
New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co:
Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…
Arbutus Biopharma jumps after claim construction order in patent fight with Moderna
…
Earnings call: Arbutus Biopharma outlines HBV strategy and financial health By Investing.com
Earnings call: Arbutus Biopharma outlines HBV strategy and financial health…